Unisound's agent business clears 5B yuan in H1, token revenue jumps 500%
Two Chinese AI stories landed today that point in opposite directions on what "working" looks like at scale: a Hong Kong-listed industry-agent company posted real growth on a Palantir-style model, and one of the country's largest healthcare AI products inked a deal to plug authoritative Western medical journals into its doctor-facing app.
Hong Kong's "AGI first stock" delivered a clean H1: revenue of 5.62 billion yuan, up 38.7% year over year, with the agent business alone accounting for roughly 85% of the total. Unisound (云知声) reported on Thursday that its enterprise intelligent services line — built from agent applications, an agent platform, and integrated solutions — hit 4.78 billion yuan in the first six months of 2026, up 35.7%. The company is the first Chinese AI firm to be marketed as an "AGI stock" in Hong Kong, and the H1 numbers are the first hard test of whether that framing maps to actual business. By the most important metric — whether the model is making money, not just spending it — the answer so far is yes. Gross margin rose to 33.1% as gross profit jumped 42% (faster than revenue), and the net loss rate narrowed by more than 31 percentage points, all while R&D spend climbed 69% to 284 million yuan. Re-purchase revenue already accounts for more than 60% of the total, the strongest signal in the report that the customers are staying.
The model underneath the numbers is the U2 family, a sparse mixture-of-experts stack with 260 billion total parameters activating roughly 10 billion per inference, which Unisound has wrapped in a medical-grade U2-Med layer plus voice and document multimodal variants. The new piece of the report is the token business — a small line in absolute terms (about 30 million yuan in H1), but with a Q2 sequential jump north of 500% and a gross margin above 60%, driven by dollar-denominated revenue and what the company calls a "high-value scenarios" strategy rather than competing on Token price. Cash on hand ballooned 302.8% to roughly 1 billion yuan, and the order backlog crossed 1.5 billion yuan, mostly from medical institutions — 470+ served in total, more than 80% of them tier-3 hospitals. The reason this story matters beyond Unisound is the structural shape: revenue and gross profit rising while R&D and backlog rise in tandem, and the loss narrowing, is the rare combination Chinese AI investors are looking for. The first Chinese labs to claim repeatable agent revenue are starting to look like software businesses with attached models, not model businesses hoping to add software later. We covered MiniMax's revenue nearly quadrupling as its model lags last week, and the H1 reports this season are quietly rewriting what the bar for "working" looks like in Chinese AI.
Ant Health plugs Wolters Kluwer's 28 top medical journals into its doctor app
Ant Group's healthcare arm, Ant Health, has signed a strategic deal with Wolters Kluwer to bring 28 of the medical publisher's flagship journals — including the Journal of Clinical Oncology and Annals of Surgery — into the Ant Afu doctor-facing app as the first phase of a deeper clinical-AI partnership. The journals cover 17 second-level medical disciplines and update in lockstep with the global editions, so doctors in China get evidence parity with their US and European peers on day one rather than waiting for translated or abridged reprints. The integration is the most concrete signal yet that China's consumer-facing medical AI is moving from "patient self-triage" into the physician's actual workflow — Afu's doctor version launched in August with an "AI medical assistant" and an "AI avatar" tool, and it already sits on top of 60 million evidence-based articles, medical guidelines, and 140,000 drug monographs.
The deal goes wider than journal access. Ant Health says clinician feedback from inside the app will flow back to Wolters Kluwer's UpToDate engine to refine its AI capabilities, with separate model tuning for tier-3 specialists, general practitioners, and primary-care doctors. The framing from Christian Cella, Wolters Kluwer's vice president for international medical markets, is the most honest version of why a Western evidence authority is interested in a Chinese AI partner: China's patient volume per doctor is so high that physician time is the binding constraint, and patients using AI for self-diagnosis paradoxically add to primary-care workload. Afu's "patient-side + doctor-side" loop, the argument goes, lets AI absorb the low-value triage work and lets humans keep the high-value clinical time — the same labor-economics pitch that drove the original wave of US clinical AI deals, just a decade and a regulatory framework behind. We covered earlier this month how China's industry ministry is laying out its five-year AI application playbook, and medical-AI deployment is one of the few areas where Beijing, US publishers, and Chinese tech are pulling in the same direction.
If the first wave of Chinese AI labs reporting earnings is finally showing the Palantir-shaped revenue curve, are the US open-weight labs next? Tell us in the comments.
Sources: QbitAI (量子位) · Sina Finance (新浪财经) · Leiphone (雷峰网) · Sohu · cn-healthcare (健康界)
